Novel Microflora Refinement System for Fecal Microbiota Transplantation
WINNER: Winner of Therapeutic Devices Category
Clostridium difficile (C. diff) is an intestinal pathogen responsible for a rise in diarrhea. While antibiotic treatment is the standard, patients have a recurrence rate of 35%, leading to $3.2 billion per year in healthcare costs. One highly effective therapeutic option is Fecal Mircobiota Transplantation (FMT) where a healthy donor provides a stool sample, which requires filtration and administration to the patient. We aim to bring FMT to the mainstream by introducing a novel collection-isolation system that separates viable bacteria from insoluble waste in stool in a closed-environment, mitigating pathogen exposure while packaging the bacteria for delivery or storage.